Skip to main content
Erschienen in: Journal of Endocrinological Investigation 12/2015

01.12.2015 | Original Article

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance

verfasst von: M. C. Amato, R. Vesco, E. Vigneri, A. Ciresi, C. Giordano

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders).

Methods

22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose infusion rate during clamp (M value); insulin secretion by Insulinogenic index, Oral Disposition Index (DIo) and AUC2h-insulin during OGTT; and insulin clearance by the metabolic clearance rate of insulin (MCRI) during clamp.

Results

Women with PCOS showed significantly higher levels of AUC2h-insulin (p < 0.011), Insulinogenic Index (p < 0.001), DIo (p = 0.002) and significantly lower levels of AUC2h-glucose (p = 0.001). No difference was found between the two groups regarding insulin sensitivity (M value). Lower levels of MCRI were found in women with PCOS [420 (IQR 227–588) vs. 743 (IQR 597–888) ml m−2 min−1: p < 0.001]. Furthermore, in the PCOS group, a strong independent inverse correlation was only observed between MCRI and AUC2h-insulin (PCOS: β:−0.878; p < 0.001; Prediabetes: β:−0.501; p = 0.019).

Conclusions

Our study suggests that in normoglycemic women with PCOS there is peripheral insulin sensitivity similar to that of women with prediabetes. What sets PCOS apart is the hyperinsulinism, today still simplistically defined “compensatory”; actually this is mainly related to decreased insulin clearance whose specific causes and dynamics have yet to be clarified.
Literatur
1.
Zurück zum Zitat Pasquali R, Gambineri A (2013) Glucose intolerance states in women with the polycystic ovary syndrome. J Endocrinol Invest 36(8):648–653CrossRefPubMed Pasquali R, Gambineri A (2013) Glucose intolerance states in women with the polycystic ovary syndrome. J Endocrinol Invest 36(8):648–653CrossRefPubMed
2.
Zurück zum Zitat Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 28:777–784CrossRefPubMed Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 28:777–784CrossRefPubMed
3.
Zurück zum Zitat Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited an update on mechanisms and implications. Endocr Rev 33:981–1030CrossRefPubMed Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited an update on mechanisms and implications. Endocr Rev 33:981–1030CrossRefPubMed
4.
Zurück zum Zitat Galluzzo A, Amato MC, Giordano C (2008) Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 18:511–518CrossRefPubMed Galluzzo A, Amato MC, Giordano C (2008) Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 18:511–518CrossRefPubMed
5.
Zurück zum Zitat Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A (1997) Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 12:1897–1901CrossRefPubMed Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A (1997) Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 12:1897–1901CrossRefPubMed
6.
Zurück zum Zitat Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1495–1607CrossRef Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1495–1607CrossRef
7.
Zurück zum Zitat De Fronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194CrossRef De Fronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194CrossRef
8.
Zurück zum Zitat Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed
9.
Zurück zum Zitat Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMedCentralCrossRefPubMed Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamäki K, Ehnholm C, Tuomilehto J, Collins FS, Bergman RN, Boehnke M (1999) Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 49:159–168CrossRefPubMed Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamäki K, Ehnholm C, Tuomilehto J, Collins FS, Bergman RN, Boehnke M (1999) Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 49:159–168CrossRefPubMed
11.
Zurück zum Zitat Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232CrossRefPubMed Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232CrossRefPubMed
12.
Zurück zum Zitat Boesgaard TW, Grarup N, Jørgensen T, Borch-Johnsen K, Hansen T, Pedersen O (2010) Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated β cell function in middle-aged Danish people. Diabetologia 53:1647–1655CrossRefPubMed Boesgaard TW, Grarup N, Jørgensen T, Borch-Johnsen K, Hansen T, Pedersen O (2010) Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated β cell function in middle-aged Danish people. Diabetologia 53:1647–1655CrossRefPubMed
13.
Zurück zum Zitat Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, Haffner SM (2010) Disposition index, glucose effectiveness, and conversion to type 2 diabetes. Diabetes Care 33:2098–2103PubMedCentralCrossRefPubMed Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, Haffner SM (2010) Disposition index, glucose effectiveness, and conversion to type 2 diabetes. Diabetes Care 33:2098–2103PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMedCentralCrossRefPubMed Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Jaspan J, Polonsky K (1982) Glucose ingestion in dogs alters the hepatic extraction of insulin. In vivo evidence for a relationship between biologic action and extraction of insulin. J Clin Invest 69:516–525PubMedCentralCrossRefPubMed Jaspan J, Polonsky K (1982) Glucose ingestion in dogs alters the hepatic extraction of insulin. In vivo evidence for a relationship between biologic action and extraction of insulin. J Clin Invest 69:516–525PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Honey RN, Price S (1979) The determinants of insulin extraction in the isolated perfused rat liver. Horm Metab Res 11:111–117CrossRefPubMed Honey RN, Price S (1979) The determinants of insulin extraction in the isolated perfused rat liver. Horm Metab Res 11:111–117CrossRefPubMed
17.
Zurück zum Zitat Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF (1972) The metabolism of proinsulin and insulin by the liver. J Clin Invest 51:912–921PubMedCentralCrossRefPubMed Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF (1972) The metabolism of proinsulin and insulin by the liver. J Clin Invest 51:912–921PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Harding PE, Bloom G, Field JB (1975) Effect of infusion of insulin into portal vein on hepatic extraction of insulin in anesthetized dogs. Am J Physiol 228:1580–1588PubMed Harding PE, Bloom G, Field JB (1975) Effect of infusion of insulin into portal vein on hepatic extraction of insulin in anesthetized dogs. Am J Physiol 228:1580–1588PubMed
19.
Zurück zum Zitat Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
20.
Zurück zum Zitat Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447CrossRefPubMed Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447CrossRefPubMed
21.
Zurück zum Zitat Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672CrossRefPubMed Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672CrossRefPubMed
22.
Zurück zum Zitat Amato MC, Verghi M, Galluzzo A, Giordano C (2011) The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 26:1486–1494CrossRefPubMed Amato MC, Verghi M, Galluzzo A, Giordano C (2011) The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 26:1486–1494CrossRefPubMed
23.
Zurück zum Zitat Christensen JT, Boldsen J, Westergaard JG (1997) Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstet Gynecol Scand 76:784–789CrossRefPubMed Christensen JT, Boldsen J, Westergaard JG (1997) Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstet Gynecol Scand 76:784–789CrossRefPubMed
24.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) 2001 expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) 2001 expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497CrossRef
25.
Zurück zum Zitat American Diabetes Association (2014) Standards of medical care in diabetes-2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef American Diabetes Association (2014) Standards of medical care in diabetes-2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef
26.
Zurück zum Zitat De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223 De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223
27.
Zurück zum Zitat Seltzer HS, Allen EW, Herron AL Jr, Brennan MT (1967) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46:323–335PubMedCentralCrossRefPubMed Seltzer HS, Allen EW, Herron AL Jr, Brennan MT (1967) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46:323–335PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341PubMedCentralCrossRefPubMed Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C (2012) Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab 97(8):2907–2915CrossRefPubMed Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C (2012) Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab 97(8):2907–2915CrossRefPubMed
31.
Zurück zum Zitat Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf) 79(6):845–852CrossRef Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf) 79(6):845–852CrossRef
32.
Zurück zum Zitat Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922PubMedCentralCrossRefPubMed Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E (2012) Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 35:1605–1610PubMedCentralCrossRefPubMed Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E (2012) Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 35:1605–1610PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174CrossRefPubMed Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174CrossRefPubMed
35.
Zurück zum Zitat Ovalle F, Azziz R (2002) Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095–1105CrossRefPubMed Ovalle F, Azziz R (2002) Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095–1105CrossRefPubMed
36.
Zurück zum Zitat Corbould A, Kim Y-B, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A (2005) Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 288:E1047–E1054CrossRefPubMed Corbould A, Kim Y-B, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A (2005) Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 288:E1047–E1054CrossRefPubMed
37.
Zurück zum Zitat Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A (2006) Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55:751–759CrossRefPubMed Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A (2006) Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55:751–759CrossRefPubMed
38.
Zurück zum Zitat Diamanti-Kandarakis E, Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 12:324–332CrossRefPubMed Diamanti-Kandarakis E, Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 12:324–332CrossRefPubMed
39.
Zurück zum Zitat Hücking K, Watanabe RM, Stefanovski D, Bergman RN (2008) OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity 16:1931–1938CrossRef Hücking K, Watanabe RM, Stefanovski D, Bergman RN (2008) OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity 16:1931–1938CrossRef
40.
Zurück zum Zitat Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW (1982) Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes 31:132–135CrossRefPubMed Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW (1982) Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes 31:132–135CrossRefPubMed
41.
Zurück zum Zitat Marshall S (1985) Kinetics of insulin receptor internalization and recycling in adipocytes. Shunting of receptors to a degradative pathway by inhibitors of recycling. J Biol Chem 260:4136–4144PubMed Marshall S (1985) Kinetics of insulin receptor internalization and recycling in adipocytes. Shunting of receptors to a degradative pathway by inhibitors of recycling. J Biol Chem 260:4136–4144PubMed
42.
Zurück zum Zitat Dunaif A, Sorbara L, Delson R, Green G (1993) Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 42:1462–1468CrossRefPubMed Dunaif A, Sorbara L, Delson R, Green G (1993) Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 42:1462–1468CrossRefPubMed
43.
Zurück zum Zitat Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti M, Melchionda N (1982) Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 14:284–287CrossRefPubMed Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti M, Melchionda N (1982) Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 14:284–287CrossRefPubMed
44.
Zurück zum Zitat Mahabeer S, Jialal I, Norman RJ, Naidoo C, Reddi K, Joubert SM (1989) Insulin and C-peptide secretion in nonobese patients with polycystic ovarian disease. Horm Metab Res 21:502–506CrossRefPubMed Mahabeer S, Jialal I, Norman RJ, Naidoo C, Reddi K, Joubert SM (1989) Insulin and C-peptide secretion in nonobese patients with polycystic ovarian disease. Horm Metab Res 21:502–506CrossRefPubMed
45.
Zurück zum Zitat Polonsky KS, Rubenstein AH (1984) C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33:486–494CrossRefPubMed Polonsky KS, Rubenstein AH (1984) C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33:486–494CrossRefPubMed
Metadaten
Titel
Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance
verfasst von
M. C. Amato
R. Vesco
E. Vigneri
A. Ciresi
C. Giordano
Publikationsdatum
01.12.2015
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 12/2015
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0372-x

Weitere Artikel der Ausgabe 12/2015

Journal of Endocrinological Investigation 12/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.